Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Revolution Medicines, Inc.
MacroGenics
AstraZeneca
National Institutes of Health Clinical Center (CC)
Celgene